Usefulness of Low Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment

High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine) can lead to a higher proportion of high-risk patients achieving target LDL-C.

Source: The American Journal of Cardiology - October 18, 2018 Category: Cardiology Authors: Giuseppe Marazzi, Giuseppe Campolongo, Francesco Pelliccia, Paolo Calabr ò, Luca Cacciotti, Cristiana Vitale, Rosalba Massaro, Maurizio Volterrani, Giuseppe Rosano Source Type: research